Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1971 1
1973 1
1974 2
1975 3
1976 5
1977 2
1978 3
1979 5
1980 1
1981 8
1983 3
1984 4
1985 4
1986 6
1987 7
1988 8
1989 4
1990 8
1991 7
1992 1
1993 7
1994 5
1995 4
1996 1
1997 1
1998 8
1999 3
2000 3
2001 6
2003 2
2004 6
2005 2
2006 3
2007 1
2008 2
2009 5
2010 1
2011 2
2012 5
2013 2
2014 4
2015 3
2016 2
2017 3
2018 4
2019 4
2020 1
2021 5
2022 7
2023 2
2024 3
2025 2
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

185 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
Gupta AA, Xue W, Harrison DJ, Hawkins DS, Dasgupta R, Wolden S, Shulkin B, Qumseya A, Routh JC, MacDonald T, Feinberg S, Crompton B, Rudzinski ER, Arnold M, Venkatramani R. Gupta AA, et al. Lancet Oncol. 2024 Jul;25(7):912-921. doi: 10.1016/S1470-2045(24)00255-9. Lancet Oncol. 2024. PMID: 38936378 Free PMC article. Clinical Trial.
Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH. Arndt CA, et al. J Clin Oncol. 2009 Nov 1;27(31):5182-8. doi: 10.1200/JCO.2009.22.3768. Epub 2009 Sep 21. J Clin Oncol. 2009. PMID: 19770373 Free PMC article. Clinical Trial.
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristin …
PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standar …
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, Gebhardt MC, Dickman PS, Perlman EJ, Meyers PA, Donaldson SS, Moore S, Rausen AR, Vietti TJ, Miser JS. Grier HE, et al. N Engl J Med. 2003 Feb 20;348(8):694-701. doi: 10.1056/NEJMoa020890. N Engl J Med. 2003. PMID: 12594313 Free article. Clinical Trial.
The patients were randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or experimental therapy with these four drugs alternating with courses of ifosfamide and etoposide. ...
The patients were randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dac …
Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial.
Chen L, Xi L, Jiang J, Yin R, Qu P, Li X, Wan X, Chen Y, Hu D, Mao Y, Pan Z, Cheng X, Wang X, Li Q, Weng D, Zhang X, Zhang H, Ping Q, Liu X, Xie X, Kong B, Ma D, Lu W. Chen L, et al. Front Med. 2022 Apr;16(2):276-284. doi: 10.1007/s11684-021-0855-4. Epub 2021 Jun 28. Front Med. 2022. PMID: 34181195 Clinical Trial.
Patients were allocated to three initiated regimens: single-course methotrexate (MTX), single-course MTX + dactinomycin (ACTD), and multi-course MTX (control arm). The primary endpoint was the complete remission (CR) rate by initial drug(s). ...
Patients were allocated to three initiated regimens: single-course methotrexate (MTX), single-course MTX + dactinomycin (ACTD), and m …
Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH. Hawkins DS, et al. J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9. J Clin Oncol. 2018. PMID: 30091945 Free PMC article. Clinical Trial.
The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses. All patients received a lower dose of cyclophosphamide …
The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan ( …
Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma.
Carli M, Pastore G, Perilongo G, Grotto P, De Bernardi B, Ceci A, Di Tullio M, Madon E, Pianca C, Paolucci G. Carli M, et al. J Clin Oncol. 1988 Apr;6(4):654-8. doi: 10.1200/JCO.1988.6.4.654. J Clin Oncol. 1988. PMID: 3357006 Clinical Trial.
This report deals with a randomized prospective multicentric clinical trial in childhood rhabdomyosarcoma (RMS) conducted to evaluate the toxicity and the effectiveness of dactinomycin (ACT-D) administered as high, single doses v five-day, divided doses administered in com …
This report deals with a randomized prospective multicentric clinical trial in childhood rhabdomyosarcoma (RMS) conducted to evaluate the to …
Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.
Khanna C, Lund EM, Redic KA, Hayden DW, Bell FW, Goulland EL, Klausner JS. Khanna C, et al. J Am Vet Med Assoc. 1998 Oct 1;213(7):985-90. J Am Vet Med Assoc. 1998. PMID: 9776993 Free article. Clinical Trial.
RESULTS: 37 dogs received at least 1 dose of doxorubicin (21 dogs) or dactinomycin (16). Median time to first remission was not significantly different between groups, but median duration of first remission and median survival time were significantly longer for dogs in the …
RESULTS: 37 dogs received at least 1 dose of doxorubicin (21 dogs) or dactinomycin (16). Median time to first remission was not signi …
Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.
Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, Provencher D, Scott Miller D, Covens AL, Lage JM. Osborne RJ, et al. J Clin Oncol. 2011 Mar 1;29(7):825-31. doi: 10.1200/JCO.2010.30.4386. Epub 2011 Jan 24. J Clin Oncol. 2011. PMID: 21263100 Free PMC article. Clinical Trial.
There were two potential recurrences; one at 4 months (dactinomycin) and one at 22 months (methotrexate). Not all patients completed follow-up. Both regimens were well tolerated. CONCLUSION: The biweekly dactinomycin regimen has a higher CR rate than the weekly IM m …
There were two potential recurrences; one at 4 months (dactinomycin) and one at 22 months (methotrexate). Not all patients completed …
Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial.
Jiang F, Guan CL, Jiao LZ, Xu T, Wan XR, Shi SS, Wu BB, Zhang X, Zhen L, Miao JW, Tian M, Du M, Li C, Feng FZ, Yang JJ, Ren T, Zhao J, Li Y, Zhang XQ, Lu X, Xiang Y. Jiang F, et al. Ann Oncol. 2025 Oct;36(10):1123-1131. doi: 10.1016/j.annonc.2025.06.006. Epub 2025 Jun 19. Ann Oncol. 2025. PMID: 40543844 Free article. Clinical Trial.
185 results